TMT-Rx (Torralva Medical Therapeutics)
TMT-Rx is a drug development company based in Portland, Oregon, focused on creating novel therapeutics to address the growing crisis of fentanyl and synthetic opioid overdose. Founded by Dr. Phillip R. Torralva, a board-certified anesthesiologist and addiction medicine specialist, the company is pioneering research into the unique mechanisms of fentanyl toxicity, particularly those resistant to current treatments like naloxone. TMT-Rx's mission is to increase survival from fentanyl overdose by developing next-generation therapeutics that target both opioid and non-opioid receptor mechanisms, with the vision of providing effective solutions for overdose reversal, medication-assisted treatment, and chemical weapon countermeasures.
TMT-Rx (Torralva Medical Therapeutics)
What We Do
Development of new drug formulations, including combination therapeutics with naloxone, to treat fentanyl and fentanyl analogue overdose, addressing both opioid and non-opioid receptor mechanisms.
A proprietary animal model developed to assess the efficacy of candidate drugs in reversing fentanyl-induced respiratory depression, chest wall rigidity, and vocal cord closure.
Research and development of novel therapeutics specifically targeting fentanyl and fentanyl analogue overdose, including mechanisms resistant to naloxone.
Assessment of three classes of drugs, individually and in combination with naloxone, using proprietary animal models to reverse fentanyl-induced respiratory depression, chest wall rigidity, and vocal cord closure.
Investigation into the mechanisms behind naloxone resistance in fentanyl overdose and identification of new drug candidates and targets.
Key People
Founder, Chief Executive Officer, Chief Scientific Officer
Vice President of Business Development
Director of Operations
News & Updates
TMT-Rx was launched in 2020 with an award from the National Institute on Drug Abuse 'Start a Substance Abuse Startup Challenge.'
TMT-Rx received a prestigious Phase I grant from the National Institutes of Health in 2021, supporting early-stage drug development.
In 2022, TMT-Rx was awarded NIDA STTR and SBIR FAST-track grants for drug development, supporting the advancement of its novel therapeutics.
TMT-Rx was selected for the I-Corps™ at NIH program and the NIH Fast-Track Small Business Innovation Research program, receiving over $1.3 million in funding to expedite commercialization of its biomedical technology.
TMT-Rx received a NIDA small business innovation research grant to investigate novel mechanisms for treatment of naloxone-resistant drug overdose.
Dr. Phillip Torralva was selected for the Yale Innovation to Impact Fellowship, a national program supporting commercialization of solutions to substance use disorder.